July 21, 2026: A cancer therapy candidate designed to target HPV-related precancerous lesions and two vaccine technologies against major enteric infections have moved one step closer to further development following technology transfer agreements facilitated by the Indian Council of Medical Research (ICMR).
Under its Medical Innovations Patent Mitra initiative, ICMR has licensed three indigenous biomedical technologies to Indian pharmaceutical and vaccine manufacturers, creating a pathway for research developed in public institutions to progress towards manufacturing, clinical development and wider healthcare application.
The technologies include SHetA2, a novel anti-HPV therapeutic candidate licensed to Emcure Pharmaceuticals Ltd., and two next-generation enteric vaccine candidates developed at ICMR–National Institute of Research in Bacterial Infections (ICMR-NIRBI), Kolkata, which have been licensed to Biological E Ltd.
The transfers represent an important stage in biomedical innovation: moving promising discoveries from research laboratories into structured development programmes where their safety, effectiveness and scalability can be evaluated.
A New Vaccine Approach Against HPV-Related Cervical Disease
SHetA2 represents a targeted approach to HPV-associated cervical disease, one of the leading causes of cervical cancer worldwide.
Developed through collaboration between ICMR-National Institute of Cancer Prevention and Research (ICMR-NICPR) scientist Dr. Showket Hussain and Dr. Doris M. Benbrook of the Stephenson Cancer Center, University of Oklahoma, USA, the candidate is designed to selectively eliminate HPV-induced precancerous and cervical cancer cells while limiting damage to healthy cells.
If successful through further development and clinical evaluation, such targeted therapies could offer alternatives to existing treatment approaches for cervical intraepithelial neoplasia (CIN), particularly in settings where access to advanced cancer care remains limited.
The development also aligns with wider efforts in cervical cancer control, where early detection, vaccination and improved treatment options are considered critical components of reducing disease burden.
Vaccine Research Targets Enteric Infections
Alongside the cancer therapy candidate, ICMR has transferred two vaccine technologies focused on bacterial infections affecting the gastrointestinal system.
Developed by Dr. Santasabuj Das and his team at ICMR-NIRBI, the candidates address diseases caused by enteric pathogens, including Salmonella typhi, which causes typhoid fever, as well as Shigella infections.
The technologies include a fusion construct using Salmonella typhi outer membrane protein as a potential next-generation typhoid vaccine candidate and a recombinant vaccine composition designed to provide broader protection against Salmonella typhi, paratyphi and Shigella infections.
These approaches are significant because enteric bacterial diseases continue to pose public health challenges, particularly due to antimicrobial resistance and the need for vaccines that provide broader and more durable protection.
Building a Research-to-Market Pipeline
The latest transfers highlight a growing focus on converting publicly funded biomedical research into products that can reach healthcare systems.
According to Dr. Rajiv Bahl, Secretary, Department of Health Research (DHR) and Director General, ICMR, initiatives such as Medical Innovations Patent Mitra are intended to strengthen collaboration between researchers and industry by supporting patent protection, licensing and commercial development.
India’s biomedical research ecosystem has increasingly focused on creating stronger links between discovery science, intellectual property management, regulatory pathways and manufacturing capabilities.
The challenge ahead will be translating these technologies through rigorous clinical evaluation, regulatory approvals and large-scale production while maintaining affordability and accessibility.
Where This Could Lead
The transfer of these technologies signals a broader shift in India’s healthcare innovation landscape—from primarily adopting medical solutions developed elsewhere to building and scaling homegrown technologies.
For cancer therapeutics, advances such as targeted molecular approaches could complement existing prevention and treatment strategies. For infectious diseases, locally developed vaccines could strengthen preparedness against endemic pathogens and support broader public health programmes.
The next phase will depend on clinical progress, manufacturing readiness and successful deployment. If these technologies move through development successfully, they could add to India’s growing portfolio of indigenous biomedical solutions serving both domestic and global healthcare needs.
